![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Exposure-Response Analyses for Efficacy (SVR12) for the Direct Acting Antiviral Regimen of Paritaprevir/r, Ombitasvir with Dasabuvir ± Ribavirin in Subjects with HCV Genotype 1 Infection
|
|
|
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Amit Khatri*1, Sven Mensing2, Thomas Podsadecki3, Walid Awni1, Rajeev Menon1, Sandeep Dutta1 1Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, United States; 2Clinical Pharmacology and Pharmacometrics, AbbVie, Ludwigshafen, Germany; 3Infectious Disease, GPRD, AbbVie, North Chicago, United States
![EASL1.gif](../images/051815/051815-4/EASL1.gif)
![EASL2.gif](../images/051815/051815-4/EASL2.gif)
![EASL3.gif](../images/051815/051815-4/EASL3.gif)
![EASL4.gif](../images/051815/051815-4/EASL4.gif)
![EASL5.gif](../images/051815/051815-4/EASL5.gif)
![EASL6.gif](../images/051815/051815-4/EASL6.gif)
![EASL7.gif](../images/051815/051815-4/EASL7.gif)
![EASL8.gif](../images/051815/051815-4/EASL8.gif)
![EASL9.gif](../images/051815/051815-4/EASL9.gif)
![EASL10.gif](../images/051815/051815-4/EASL10.gif)
![EASL11.gif](../images/051815/051815-4/EASL11.gif)
![EASL12.gif](../images/051815/051815-4/EASL12.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|